SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund (USO) is trending with extreme volatility as escalating Middle East tensions and threats to global oil supply from the Strait of Hormuz have driven a sharp price surge. However, community sentiment is now divided between those anticipating sustained higher prices and those expecting a rapid pullback following G7 discussions and actions concerning the release of strategic oil reserves.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is highly active as bullish investors enthusiastically rally around the CEO's recent comments hinting at "curative outcomes" for its lead AML immunotherapy, GPS, driving significant short squeeze speculation and expectations for imminent positive trial readouts.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is experiencing a massive surge after partnering with Novo Nordisk to offer branded GLP-1 weight-loss medications, ending a significant legal dispute and fueling widespread community discussion about a potential short squeeze and a fundamental shift in the company's growth trajectory.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is seeing significantly increased trading volume and speculation following a $40 million private placement financing and an analyst upgrade to Outperform with a $5 price target. The community is actively debating the financing's impact and the potential for a short squeeze in this catalyst-driven biotech, while also weighing ongoing pipeline developments.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is trending as its Cocky Wings LLC real-world asset business actively generates revenue, which the community is celebrating for fueling token buybacks and robust growth within its Cardano-based ecosystem and staking arena.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following positive 12-month Phase 2 interim data for its bladder cancer candidate NDV-01, which showed a durable 76% complete response rate and reinforced plans for Phase 3 trials. This, combined with an oversubscribed $160 million private placement, is driving significant trading volume and community discussion.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

SCO, an inverse crude oil ETF, is trending amidst extreme volatility in oil prices driven by escalating geopolitical tensions in the Middle East and conflicting narratives surrounding the Strait of Hormuz. The community is actively debating if crude oil is overbought and ripe for a substantial pullback, making SCO an attractive yet scrutinized play for a downturn.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is a battleground stock as the community debates whether concerns over rising fuel costs from the Iran war, potentially delaying airline orders, outweigh the impact of a massive rumored aircraft deal from China and anticipated increases in defense spending.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending amidst a contentious lawsuit from rival Archer Aviation alleging deceptive ties to Chinese suppliers, even as the company celebrates the official launch of Uber Air in Dubai, signaling a major step towards commercial air taxi service. Community discussion is further fueled by recent earnings highlighting revenue growth and a strong cash runway, with ongoing focus on FAA certification progress and competitive dynamics within the eVTOL sector.

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corp.

Calamp Corp.

CAMP4 Therapeutics is capturing significant attention following its oversubscribed $100 million private placement, aimed at advancing its SYNGAP1-related disorder treatment into trials. The community is actively discussing its low float and the potential for a short squeeze, alongside anticipation for upcoming clinical milestones and a recent collaboration with GSK.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action?

AN2 Therapeutics Inc (NASDAQ: ANTX) shares are surging Monday afternoon after the company announced a $40 million private placement financing.read more...

<ul class="summary-bullets"><li>AN2 Therapeutics is expected to sell more than eight million shares of common stock at $2.85 per share.</li><li>The private placement includes participation from institutional investors such as Coastlands Capital, Commodore Capital, and Vivo Capital.</li><li>The stock has gained more than&nbsp;500% over four sessions since the company announced positive results for its blood cancer treatment.</li></ul>Shares of AN2 Therapeutics (ANTX) surged more than 110% on Monday, after the clinical-stage biopharmaceutical company announced that it signed a securities purchase agreement for a private placement expected to raise about $40 million in gross proceeds.<a href="https://stocktwits.com/symbol/ANTX">ANTX shares</a> recorded their biggest-ever intraday gains.As part of the deal, AN2 Therapeutics will sell 8.25 million shares of common stock at $2.85 per share, which was also the stock’s closing price on Friday. The company also offered investors the option to purchase pre-funded warrants to acquire up to 5.79 million additional shares at nearly the same price, with an exercise price of&nbsp;$0.00001 per share.The private placement is expected to close on March 10, 2026, and includes participation from institutional investors such as Coastlands Capital, Commodore Capital, and Vivo Capital, along with other new and existing shareholders. AN2 Therapeutics did not disclose how it plans to use the proceeds from the offering.<h2 class="st-heading-2">500% Rally After Epetraborole Update</h2>The stock has been on an extraordinary rally, adding nearly 500% over four sessions since the company announced plans to further develop its drug epetraborole into a Phase 2 proof-of-concept study for patients with Polycythemia Vera (PV) who rely on phlebotomy treatments.PV is a blood cancer that causes the bone marrow to produce too many red blood cells, increasing the risk of serious complications such as blood clots.Last week, AN2 Therapeutics said that its oral epetraborole produced consistent and sustained reductions in hematocrit across several studies involving healthy volunteers and other patient groups. The company expects to begin the Phase 2 study in the third quarter of 2026 and plans to provide initial trial updates by the following quarter.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/ANTX_jpg_31ad151992.webp" alt="ANTX.jpg">One user highlighted the various resistance levels, speculating that the stock could climb as high as $108.<stembedurl>https://stocktwits.com/M105/message/647014265</stembedurl>However, another expressed confusion over the “bullish excitement.”<stembedurl>https://stocktwits.com/Tradeforlosses/message/647018987</stembedurl>Year-to-date, the stock has gained more than 400%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/iran-warns-of-crude-hitting-200-a-barrel-if-energy-infrastructure-is-targeted-report/cZdVpreRIIr">Iran Warns Of Crude Hitting $200 A Barrel If Energy Infrastructure Is Targeted: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ANTX Stock Records Biggest Ever Single Day Gain, Surges 500% Over Past Four Sessions – What Triggered This Smashing Rally?

AN2 Therapeutics shares more than doubled in value on Monday after the company announced a private placement to raise about $40 million.

Equity

AN2 Therapeutics Announces $40 Million Private Placement Financing

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has...

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to...

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder...

AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the U.S. Food and Drug...

AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?

AN2 Therapeutics (ANTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging  Allogene Therapeutics (ALLO) This Year?

Here is how Allogene Therapeutics (ALLO) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported...

AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a collaboration agreement with the...

Iran / Geopolitical tensions

Fed speakers

Macro data

Earnings

What will be the primary market driver this week?

Stocktwits

Stocktwits Polls

Users are celebrating massive gains, with one news article citing a 500% surge over four sessions and others expecting prices to reach $9, $12, or even $24.

Traders anticipate a significant short squeeze, with many believing bearish bets are getting "burned" as the stock continues to climb rapidly.

The announcement of a $40 million private placement financing at $2.85 per share is a major talking point, raising both excitement and concerns about potential dilution.

Many users suspect institutional investors have locked the stock's float, driving speculative trading and sharp price movements.

ANTX
AN2 Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANTX News

ANTXAN2 Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANTX News

ANTX
AN2 Therapeutics Inc